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Abstract: The use of sublingual captopril and
nifedipine has been indicated in hypertensive
emergencies and in patients with essential
hypertension, with the assumption that by
this route, there would be a faster absorption
and thus a more rapid effect on blood
pressure (BP) than by the oral route.
A comparative study of the effects of
Losartan, angiotensin II receptor antagonist,
captopril and nifedipine on blood pressure
was carried out in patients with hypertensive
urgency.
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Sixty patients with hypertensive urgency
were subdivided into 3 groups of 20 patients
each. The first group received sublingual
captopril (25 mg), the second group received
sublingual nifedipine (10 mg) and the third
group received sublingual losartan (50 mg).
In the captopril, nifedipine and losartan
groups, the mean systolic pressures at the
onset of hypertensive urgency were

Introduction
Hypertensive emergency is defined as severe elevation
in blood pressure (BP) with signs or symptoms of acute,
severe target organ damage that must be reduced within
minutes (1, 2). Hypertensive urgency is defined as severe
elevation in BP with mild or no acute target organ
damage which must be reduced within hours1,2. The
appropriate medication for the treatment of hypertensive
emergencies and hypertensive urgencies should have the
following properties: Availability for nonparenteral
administiration,
managing
peripheral
vascular
vasodilatation and decrease BP to a plateau(3, 4).
Recent studies have demonstrated the effectiveness of
sublingually administered nifedipine and captopril in
rapidly reducing arterial pressure in hypertensive
emergencies and in patients with essential
hypertension(5, 6).

188.00±23, 190.00±35 and 190.50±21
mmHg respectively. At 90 minutes, in the
captopril, nifedipine and losartan groups, the
mean systolic blood pressures were
138.50±18, 144.50±25 and 146.25±21
mmHg respectively. In the captopril,
nifedipine and losartan groups, the mean
diastolic blood pressures at the onset of
hypertensive urgency were 116.00±15,
121.50±22 and 109.25±14 mmHg
respectively. In the captopril, nifedipine and
losartan groups, at 90 minutes, mean
diastolic blood pressures were 84.75±10,
95.25±19
and
88.50±12
mmHg
respectively. A significant (P<0.05)
hypotensive effect of sublingual captopril,
nifedipine and losartan therapy occurred at
90 minutes. The results of the study indicate
that sublingual losartan is an effective drug in
patients with hypertensive urgency
Key Words: Hypertensive Urgency, Losartan

Losartan, angiotensin II receptor antagonist, blocks
vasoconstriction caused by angiotensin II(7). Our study is
a comparative evaluation of the effects of sublingually
administered losartan, captopril and nifedipine on
hypertensive urgency.
Patients and Method
The 60 patients who participated in this study were
subdivided into three groups: 20 patients (12 female and
8 male, mean age 49.35±12.62 years) in the captopril
group, 20 patients (9 female and 11 male, mean age
47.85±13.99 years) in the nifedipine group, and 20
patients (11 female and 9 male, mean age, 47.70±90.85
years) in the losartan group.
All patients had BP higher than 180/100 mmHg in
three different measurements, 15 minutes apart. Patients
who had no signs or history of cerebrovascular disease,
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myocardial disease, diabetes mellitus, or renal disease,
were included in this study. Secondary forms of
hypertension were ruled out after careful clinical and
laboratory evaluations. Patients who had a history of
hypertension but had not taken an antihypertensive agent
for at least 24 hours were chosen. The patients rested in
the supine position for at least 20 minutes before the test
began. BP measurements were made with a mercury
sphygmomanometer. The values used were obtained from
the average of three consecutive measurements. The
diastolic arterial pressure was recorded at the
disappearance of Korokoff sounds (phase V). Mean blood
pressure (MBP) was measured by the following formula:
2 x Diastolic Blood Pressure (DBP) + Systolic Blood
Pressure (SBP)/3. BP was measured before and 15, 30,
60 and 90 minutes after the administration of the drugs.
The captopril group was treated with 25 mg captopril,
the nifedipine group with 10 mg nifedipine, and the
losartan group with 50 mg losartan. All drugs were
administered sublingually. The patients were shown how
to crush the captopril tablet and the losartan tablet and
how to pierce the nifedipine capsule, and were told to
wait for the drug to completely dissolve under the
tongue. Statistical analysis of the results was carried out

ONSET SBP
ONSET DBP
15 min SBP
15 min DBP
30 min SBP
30 min DBP
60 min SBP
60 min DBP
90 min SBP
90 min DBP

by BMDP2 V – analysis variance and covariance with
repeated measures.
Results
There was no significant difference between the
demographic data of the 3 treatment groups. In the
captopril group, mean (±SD) SBP and DBP dropped from
188.00±23 to 138.50±18 mmHg and from 116.00±15
to 84.75±10 mmHg respectively at 90 minutes. In the
nifedipine group, mean SBP and DBP dropped from
190.00±35 to 144.50±25 mmHg and from 121.50±22
to 95.25±19 mmHg respectively at 90 minutes. In the
losartan group, mean SBP and DBP dropped from
190.50±21 to 146.25±21 mmHg and from 109.25±14
to 88.50±12 mmHg respectively at 90 minutes. The
mean pre- and post-dose SBP and DBP in the 3 treatment
groups are summarized in Table I. The mean SBP and
DBP data before and up to 90 min after both sublingual
doses are shown in Figures 1 and 2, respectively. No
significant difference was observed in the magnitude of
the SBP- or DBP- lowering effect between the captopril,
nifedipine and losartan groups (P>0,05). The specified
total of patients who had a 20% reduction in SBP and

Captopril group

Nifedipine group

Losartan group

188.00±23.30
116.00±15.00
162.75±29.97
97.25±18.31
152.75±30.23
91.50±14.24
144.50±25.65
88.50±13.96
138.50±18.14
84.75±10.44

190.00±35.83
121.50±22.54
164.50±35.90
106.50±25.34
162.50±31.60
106.75±21.53
150.25±29.22
97.25±20.67
144.50±25.49
95.25±19.29

190.50±21.63
109.25±14.16
168.25±24.02
96.75±15.06
157.00±22.44
92.25±12.92
144.00±24.36
89.75±13.22
146.25±21.69
88.50±12.47

Captopril group

Nifedipine group

Losartan group

15 min SBP

4

4

4

15 min DBP

6

6

5

15 min MAP

6

4

4

30 min SBP

8

5

9

30 min DBP

11

3

6

30 min MAP

11

4

5

60 min SBP

10

8

13

60 min DBP

12

9

9

60 min MAP

12

6

8

90 min SBP

13

13

14

90 min DBP

14

11

8

90 min MAP

15

11

8
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Table 1.

The mean pre-and postdose
SBP, DBP in the three
treatment groups (mm Hg).

Table 2.

Specified total of patients who
had a 20% reduction in SBP,
DBP and MAP at 15, 30, 60
and 90 min.
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SBP (mmHg)

Figure 1.

Mean SBP variability in 3
groups of patients at 0, 15,
30, 60 and 90 min

Figure 1.

Mean SBP variability in 3
groups of patients at 0, 15,
30, 60 and 90 min

200
180
160
140
120

Captopril
Nifedipine

100

Losartan

80
60
40
20
0
15

30

60

90
Min.

DBP (mmHg)
140
120
100
Captopril

80

Nifedipine
Losartan

60
40
20
0
15

30

60

90
Min.

DBP and mean arterial pressure at 15, 30, 60 and 90 min
are shown in Table II and Figures 3 and 4.
In the nifedipine group, a 20% reduction in DBP
occurred in 6 patients at 15 min, but at 30 min this
reduction occurred in 3 patients. This DBP increase in 3

patients did not occur in the other groups (P<0.05). Preand post-dose measurements of BUN, electrolytes,
creatinine, LDH, SGOT, SGPT and glucose levels were all
observed to be within the normal range in all patients. No
abrupt decrease in BP occurred in the patients.
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Figure 3.
14

12

The specified total of patients
who had a 20% reduction in
SBP at 15, 30, 60 and 90 min
when compared with initial
blood pressures.
Losartan
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Nifealipine
8

Captopril
6

4
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0
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Figure 4.
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The specified total of patients
who had 20% reduction in
DBP at 15, 30, 60 and 90
min. compared with initial
blood pressures.
Losartan

10

Nifealipine
8

Captopril

6

4

2

0
15

30

60

90
Minutes

Discussion
Many antihypertensive agents such as captopril and
nifedipine are used in hypertensive emergencies and
hypertensive urgencies(3, 4, 8, 9). Some reports suggest
the superiority of captopril to nifedipine, whereas others
recommend nifedipine for hypertensive emergencies(6, 9,
10). Recently, a review of multiple clinical trials has
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revealed that short-acting nifedipine may cause an
increase in mortality(11). It is recommended that patients
with coronary artery disease (CAD), especially those with
acute coronary syndromes, not receive short–acting
nifedipine. Because of its potent vasodilatator effects,
nifedipine is contraindicated in patients with unstable
angina in whom reflex mediated increases in heart rate
may be harmful(11, 12, 13).

Y. GÖKEL, S. PAYDAS, S. SATAR

The level to which blood pressure should be reduced
in patients with hypertensive emergencies and
hypertensive urgencies is still unclear and controversial.
The initial aims of therapy should be reduction of blood
pressure by one-third or 20 to 25 percent(14, 15, 16).
The initial aims of the therapy in mild and moderate
hypertension should be reduction of 5 to 10 mmHg in
blood pressure at each step(17).
Our patients were in hypertensive urgency.
Hypertensive urgency is between mild-moderate
hypertension and hypertensive crisis from the point of
view of severity. Because of this, a 20% decrease in
arterial pressure was determined.
In our study in the nifedipine group, a 20% reduction
of DBP occurred in 6 patients at 15 min, but at 30 min,
a 20% reduction of DBP occurred in 3 patients. In three
of these 6 patients, DBP was increased again, which
obviously indicates a disadvantage of nifedipine.

We concluded that the hypotensive effects of
sublingual captopril and losartan were more powerful
than those of sublingual nifedipine. We also concluded
that losartan sublingually administered is an effective and
safe alternative drug for managing hypertensive urgency.
It may be used as a first-line drug in the treatment of this
condition, since it is easy to administer.
Thus sublingual losartan appears to be the most
promising, while further studies are obviously necessary
to compare it to other antihypertensive regimens used for
the treatment of hypertensive urgencies.
Corresponding Author:
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Çukurova University Faculty of Medicine
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01330 Adana-TURKEY
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